A Phase 2 trial of mezagitamab in immune thrombocytopenia (ITP) reported that the investigational antibody substantially increased platelet counts, marking a near-term clinical proof point for a new immunotherapy mechanism in the platelet disorder space. ITP is driven by immune-mediated platelet destruction and impaired production. The results were framed around platelet response magnitude and durability, with mezagitamab designed to modulate the underlying immune pathways contributing to low platelet levels. (ITP is an autoimmune condition in which patients experience abnormally low platelets and bleeding risk.) For the broader market, the data strengthen the competitive field of next-generation ITP therapies beyond conventional steroids and splenectomy strategies and can inform Phase 3 trial design around response rates and clinically meaningful bleeding endpoints. The development adds urgency for treatment differentiation in chronic ITP, where speed of platelet recovery and tolerability often determine adoption in hematology practice.